DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Upgraded by Wall Street Zen

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

Several other analysts also recently commented on the company. Lake Street Capital increased their price objective on DiaMedica Therapeutics from $11.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, July 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of DiaMedica Therapeutics in a report on Saturday, September 27th. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Finally, Craig Hallum boosted their price target on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Friday, July 18th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, DiaMedica Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

DiaMedica Therapeutics Stock Performance

DMAC opened at $7.07 on Friday. The business's fifty day moving average is $6.00 and its 200-day moving average is $4.68. The firm has a market cap of $365.44 million, a P/E ratio of -10.25 and a beta of 1.40. DiaMedica Therapeutics has a 52-week low of $3.19 and a 52-week high of $7.49.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). On average, research analysts predict that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DiaMedica Therapeutics news, major shareholder Jan Stahlberg bought 50,772 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was bought at an average cost of $6.00 per share, for a total transaction of $304,632.00. Following the completion of the transaction, the insider owned 7,764,465 shares of the company's stock, valued at $46,586,790. This represents a 0.66% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired a total of 2,542,857 shares of company stock worth $11,358,598 in the last three months. 7.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey bought a new position in shares of DiaMedica Therapeutics during the 2nd quarter valued at approximately $29,000. Bank of America Corp DE increased its holdings in DiaMedica Therapeutics by 3,710.3% during the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company's stock worth $33,000 after purchasing an additional 8,274 shares during the period. JPMorgan Chase & Co. purchased a new stake in DiaMedica Therapeutics in the second quarter worth about $49,000. Invesco Ltd. purchased a new position in DiaMedica Therapeutics during the second quarter valued at approximately $54,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of DiaMedica Therapeutics in the 2nd quarter worth $56,000. Institutional investors own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.